AOD-9604: research overview

The short version

AOD-9604 is a 16-amino-acid synthetic peptide — a hexadecapeptide — modelled on the C-terminal portion of human growth hormone. It was engineered to reproduce hGH's fat-burning domain without activating the growth hormone receptor, which means it does not raise IGF-1, does not cause water retention, and does not drive the growth-promoting side effects associated with intact hGH.

In obese mice, it reduced body fat and increased fat-burning signals ^[4][5]. In humans, it did not. A clinical programme of roughly 900 subjects across six trials — durations from 7 days to 24 weeks — found that oral AOD-9604 was well tolerated and safe, but failed to produce statistically significant weight loss compared to placebo ^[3]. The obesity development programme was discontinued after that result. It is not FDA-approved for any indication, and the World Anti-Doping Agency classifies it as a prohibited S2 substance at all times in competition.

What it is

AOD-9604 — formally Anti-Obesity Drug 9604 — is a synthetic analogue of hGH residues 177–191, with a tyrosine substituted for the native phenylalanine at the N-terminus. The reported sequence is YLRIVQCRSVEGSCGF; the two cysteines form an intramolecular disulfide bridge that mirrors the cystine loop of the parent hormone.

The molecule was developed by Metabolic Pharmaceuticals (Melbourne) as an oral anti-obesity candidate on the hypothesis that the C-terminal domain of hGH carries its fat-metabolising activity. Non-clinical evaluation found it free of genotoxic and toxicological concerns after chronic oral administration in rats and primates; IV pharmacokinetics showed a half-life of approximately 3 minutes, with in vivo degradation by sequential N-terminal amino-acid removal ^[2]. It is not a supplement, not a nutraceutical in the conventional sense, and not a DEA-controlled substance. Its 503A compounding status before the FDA Pharmacy Compounding Advisory Committee (docket FDA-2024-N-4777, December 2024) should be independently verified — status as of this writing is not confirmed.

How it works

The mechanistic case for AOD-9604 rests on a series of in vitro and rodent studies characterizing the C-terminal domain of hGH as the portion responsible for lipid metabolism.

The foundational mechanism, established in adipocyte and hepatocyte preparations in 1983, is inhibition of acetyl-CoA carboxylase (ACC) — the enzyme that catalyzes the first committed step of fatty acid synthesis. The inhibition is indirect: the peptide interacts with plasma-membrane binding sites and releases a second messenger that increases ACC phosphorylation and inactivation, thereby suppressing de novo lipogenesis ^[7]. Subsequent rodent work characterized AOD-9604 as a synthetic lipolytic/antilipogenic domain of hGH, localizing fat-metabolism activity to this C-terminal region ^[6].

In obese mice treated chronically with AOD-9604, body fat was reduced and beta-3 adrenergic receptor (beta3-AR) expression in white adipose tissue was increased ^[4]. The beta3-AR is a key regulator of thermogenesis and lipolysis in adipocytes. Knockout studies clarified the dependency: chronic fat loss required functional beta3-AR signaling, while acute increases in fat oxidation and energy expenditure persisted even without it ^[4]. A companion study confirmed the fat-oxidation and weight-loss effect in obese mice ^[5].

The growth-hormone receptor is not engaged by AOD-9604, which is why it does not raise IGF-1 or produce the tissue-building and fluid-retaining effects of intact hGH — this receptor-sparing design was the drug's central engineering rationale ^[6].

What the research shows

The evidence base is a clear two-tier story: animal models supported the mechanism; human trials did not deliver a clinical endpoint.

Rodent and cell data (supportive)

Multiple studies in obese mice documented reduced body weight and fat mass, increased fat oxidation, and elevated beta3-AR expression following chronic AOD-9604 administration ^[4][5][6]. The acetyl-CoA carboxylase inhibition mechanism was demonstrated in adipocyte and hepatocyte preparations ^[7]. A collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits showed reduced cartilage degeneration scores after intra-articular injection — a secondary line of research unrelated to the primary obesity program ^[1].

Human data (negative for primary endpoint)

Stier et al. (2013) summarized the full human clinical programme: approximately six trials, roughly 900 obese subjects, oral doses ranging from 0.25 mg to 54 mg daily, durations from 7 days to 24 weeks ^[3]. Safety and tolerability were indistinguishable from placebo across the programme. The primary obesity endpoint — statistically significant weight loss versus placebo — was not met. The development programme was discontinued circa 2007. No published peer-reviewed report of a positive human weight-loss signal from AOD-9604 in a placebo-controlled trial has been identified.

A non-clinical safety review (2014) confirmed no genotoxic or toxicological concerns after chronic oral dosing in rats and primates, and characterized the very short IV half-life (~3 minutes) with in vivo degradation by N-terminal amino acid removal ^[2].

Evidence tier: Mechanism established in vitro and in rodent models. Human translation: no efficacy signal in placebo-controlled trials. The preclinical-to-human gap for this compound is large and documented.

Reported effects, cautions & safety

The following community reports are anecdotal, not clinical evidence. They are included because they represent the pattern of real-world experience reported in peptide research communities — and because the gap between those reports and the published human evidence is itself informative.

Community signals:

• No noticeable fat loss is the most common report — consistent with the null human trials ^[3].
• Well tolerated overall: most report few side effects, matching the published finding of placebo-equivalent tolerability ^[3].
• No GH-type side effects (no water retention, no joint puffiness, no IGF-1 effects) — consistent with the receptor-sparing design.
• Mild energy lift or sense of well-being: a minority report, not supported by any trial endpoint, plausibly attributable to concurrent lifestyle changes.
• Local injection-site redness or irritation: occasional, generic to subcutaneous peptide injection.
• Claims of localized fat loss: anecdotal and biologically implausible; spot lipolysis by injection site is not supported by physiology or any human trial.

Published safety cautions:

AOD-9604 is not FDA-approved and carries no approved indication, dosing standard, or quality control requirement for human use ^[3]. The human weight-loss efficacy signal was not demonstrated in the pivotal trial programme ^[3]. The fat-metabolism mechanisms — ACC inhibition, beta3-AR upregulation, increased fat oxidation — were characterized primarily in mouse, rat, and cell models, and these mechanistic findings did not translate into a proven human fat-loss effect ^[6][4]. The rodent-to-human translational gap for this compound illustrates a general pattern in obesity pharmacotherapy ^[6]. Long-term human safety data beyond 24 weeks does not exist in the published literature ^[3]. Subcutaneous human pharmacokinetics have not been published in peer-reviewed literature.

Regulatory caution: AOD-9604 is classified under WADA Prohibited List Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone fragment and is prohibited at all times in sport. Dedicated anti-doping assays can detect it even though it does not interfere with the standard hGH isoform immunoassay.

Where it fits in the metabolic picture

Among the three compounds on this desk, AOD-9604 occupies a distinctive position: the most mechanistically studied for pure lipolysis, and the one with the clearest negative human result. The ACC inhibition and beta3-AR upregulation mechanisms are real — the question the human trials answered is whether those mechanisms, at the doses achievable in people, produce a clinically meaningful fat-loss effect. The answer from the Phase IIb programme is that they do not, at least not to a statistically significant degree in the studied population.

For the researcher comparing approaches to metabolic intervention, AOD-9604 is a case study in how compelling preclinical mechanism does not guarantee clinical translation — a pattern noted in reviews of obesity pharmacotherapy ^[6]. Tirzepatide, reviewed on the adjacent tirzepatide page, represents the opposite trajectory: a mechanism (dual incretin agonism) that survived human Phase 3 testing at scale. MOTS-c sits at an earlier stage still: mechanism characterized in cells and animals, human interventional data absent [see /mots-c].